GlassScriptPhysician profile
Vernon D Potter
NPI 1801937263
$1,286.42
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $396 · 2021: $255 · 2022: $301.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $496.82 | 2019-2022 | |
| Pfizer INC. | $218.09 | 2019-2020 | |
| Lucid Diagnostics INC. | $157.28 | 2021-2022 | |
| Novo Nordisk INC | $121.84 | 2019 | |
| Lilly USA, LLC | $81.44 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $55.01 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.45 | 2020 | |
| Ibsa Pharma INC. | $24.65 | 2020 | |
| Eisai INC. | $24.25 | 2020 | |
| Amgen INC. | $15.57 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.52 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.90 | 2021 | |
| Mannkind Corporation | $11.83 | 2021 | |
| Shire North American Group INC | $11.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vernon Potter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.